Biotech Companies Continue to Make Progress on ESG | Fenwick & West LLP

A Look at the Disclosure Practices of Small and Mid-Size Companies –

In our report we continue to look at the progress that smaller public biotech companies have made in their reporting on environmental, social and governance (ESG) matters, building on our prior research. This year we reviewed the disclosure practices of 74 biotech companies with market capitalizations ranging from $1 billion to $10 billion as of June 30, 2023.

Please see full publication below for more information.

Leave a Comment

Your email address will not be published. Required fields are marked *